Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: Brander who wrote (435)	12/24/1997 9:31:00 PM
From: David D.	Respond to of 834

Pay no attention to those throwing stones at TXB. I have been familiar with TXB for about 4 years now. My administrative assistant's husband is a scientist for them. Although she has never been able to tell me information that is secret, I have been plugged in to TXB. Her husband has traveled to foreign countries showing off the drugs of TXB. Novastan is for real and they are extremely excited about Smith Klines support. Although the FDA has not approved the drug yet, Smith Kline would NOT be investing in it at this stage had they not done there home work. Just sit back and relax. Spring is anticipated to bring approval. Also, the asthema drug has even bigger potential than Novastan. TXB is a company that you should continue to accumulate on dips. David D.